# A Treatment Study of Mucopolysaccharidosis Type IIIB

> **NCT02754076** · PHASE1,PHASE2 · COMPLETED · sponsor: **Allievex Corporation** · enrollment: 23 (actual)

## Conditions studied

- MPS III B
- Mucopolysaccharidosis Type IIIB

## Interventions

- **DRUG:** AX 250

## Key facts

- **NCT ID:** NCT02754076
- **Lead sponsor:** Allievex Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2020-06-24
- **Final completion:** 2020-07-31
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2020-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02754076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02754076, "A Treatment Study of Mucopolysaccharidosis Type IIIB". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02754076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*